Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis

OBJECTIVE: To evaluate clinical outcomes in patients who changed treatment from adalimumab to baricitinib, an oral Janus kinase (JAK)1/JAK2 inhibitor, during a phase III programme. METHODS: In phase III RA-BEAM, patients were randomised 3:3:2 to placebo, baricitinib 4 mg once daily, or adalimumab 40...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Yoshiya, Fautrel, Bruno, Keystone, Edward C, Ortmann, Robert A, Xie, Li, Zhu, Baojin, Issa, Maher, Patel, Himanshu, Gaich, Carol L, de Bono, Stephanie, Rooney, Terence P, Taylor, Peter C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585288/
https://www.ncbi.nlm.nih.gov/pubmed/31040122
http://dx.doi.org/10.1136/annrheumdis-2018-214529

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585288/
https://www.ncbi.nlm.nih.gov/pubmed/31040122
http://dx.doi.org/10.1136/annrheumdis-2018-214529

Ejemplares similares